Calcium channel blockers cut risk of Parkinson's disease

People taking a widely used group of drugs known as calcium channel blockers to treat high blood pressure also appear to be cutting their risk of Parkinson's disease, according to a study published in the February 6, 2008, online issue of Neurology, the medical journal of the American Academy of Neurology.

The study involved 7,374 men and women over age 40. Half of the group had Parkinson's disease; the other half did not have Parkinson's disease. Among both groups, nearly half used high blood pressure medications, such as calcium channel blockers, ACE inhibitors, AT II antagonists and beta blockers.

The study found people who were currently long-term users of calcium channel blockers to treat high blood pressure lowered their risk of Parkinson's disease by 23 percent compared to people who didn't take the drugs. There was no such effect among people taking ACE inhibitors, AT II antagonists and beta blockers.

“Long-term use of calcium channel blockers was associated with a reduced risk of developing Parkinson's disease while no such association was seen for other high blood pressure medicines,” said study author Christoph R. Meier, PhD, MSc, with University Hospital Basel in Switzerland.

Meier says more research is needed to determine why calcium channel blockers appear to protect against Parkinson's disease, whether this is indeed a causal association, and why the other high blood pressure medications do not offer a reduced risk.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study paves way for revolutionizing the management of muscle disorders